Company / Profit Margin
NovaBay Pharmaceuticals, Inc. Profit Margin History
FY2015-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-40.6%
FY2017
5-year range
-
FY2015-FY2017
Trend
+63.3%
vs FY2016
Sector context
#86 of 143
Health Care
What the data says
At -40.6%, NovaBay Pharmaceuticals, Inc.'s profit margin ranks #86 of 143 in the Health Care sector. Improved from -433.1% to -40.6% over the past 2 years.
Based on SEC 10-K filings.
-40.6% in FY2017.
Improved from -433.1% to -40.6% over the past 2 years.
Health Care sector context is included.
Profit Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#86 of 143 in Health CareTop 60% of 143This company -40.6% Sector average -899.4%
▼
+95.5% above sector average
Key checks
Key Insights
- In FY2017, profit margin increased 63.3% year-over-year.
- Currently 858.8pp above the Health Care sector average.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | -40.6% | +63.3% |
| FY2016 | -110.5% | +74.5% |
| FY2015 | -433.1% | +89.5% |
As of FY2017 · SEC 10-K · Updated Feb 28, 2026